retatrutide mechanism triple agonist gip glp-1 glucagon From Obesity to Metabolic Health: Why Is a Game-Changer What Is Retatrutide? The Triple

Greenway, F.L

The common link is that GLP-1s activate receptors that then work on driving down metabolic risk factors through the following mechanisms: Enhancing glucose dependent insulin secretion Slowing gastric emptying and decreasing appetite Reducing postprandial glucagon and food intake UpToDate 2 : (1) ingestion of food results in (2) release of gastrointestinal peptides (GLP-1 and GIP: glucose-dependent insulinotropic polypeptide, gastric inhibitory peptide) and (3) pancreatic beta cell hormones (insulin and amylin)

These agents require careful dose titrations due to their adverse drug event (ADE) profile, which commonly includes nausea and vomiting

Clinicians usually start GLP-1s at a low dose to avoid nausea and other side effects, then slowly increase the dose every 1 to 4 weeks based on your tolerance and blood sugar response

Furthermore, the possible promotion of cancer cell growth is increasingly being discussed with contradictory results (Table 4) that require clarification

The upfront costs of GLP-1s are an ongoing concern for both public and private payers, and some employers and state Medicaid programs are now restricting coverage, despite recognizing their effectiveness at treating obesity